Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1/A IPO registration
- 1.1 Underwriting Agreement
- 5.1 Opinion on Legality
- 10.69 Board Service Agreement with Rajesh Shrotriya, Dated January 12, 2021.
- 10.70 Board Service Agreement with Michael Breen, Dated January 12, 2021.
- 10.71 Amendment to Settlement Note with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B.
- 10.72 Form of Securities Purchase Agreement - December 2020 / January 2021 Notes.
- 10.73 Form of December 2020 / January 2021 Note.
- 23.1 Consents of Experts and Counsel
- Download Excel data file
- View Excel data file
Associated filings
- 23 Apr 21 EFFECT Notice of effectiveness
- 22 Apr 21 POS AM Prospectus update (post-effective amendment)
- 12 Feb 21 424B4 Prospectus supplement with pricing info
- 11 Feb 21 EFFECT Notice of effectiveness
- 9 Feb 21 S-1/A IPO registration (amended)
-
8 Feb 21 S-1/A IPO registration (amended)
- 2 Feb 21 S-1/A IPO registration (amended)
- 11 Dec 20 S-1 IPO registration
GTBP similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Registration Statement on Form S-1 of GT Biopharma, Inc. of our report dated March 27, 2020, relating to our audit of the consolidated financial statements as of and for the years ended December 31, 2019 and 2018, which appears in the Annual Report on Form 10-K of GT Biopharma, Inc. for the year ended December 31, 2019. Our report included an explanatory paragraph expressing substantial doubt about the ability of GT Biopharma, Inc. to continue as a going concern.
We also consent to the reference to our Firm under the caption “Experts” in the Prospectus, which is part of this Registration Statement.
/s/Seligson & Giannattasio, LLP
Seligson & Giannattasio, LLP
White Plains, New York
February 8, 2021